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Background: Patients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival
rate because of possible curative resection. However, up to 10% of these patients relapse postoperatively. To identify
unfavorable prognostic factors, we retrospectively analyzed the clinicopathological features of p-Stage IA disease,
focusing on vascular invasion.
Methods: Of 467 patients with p-Stage I NSCLC, 335 were diagnosed with p-Stage IA or IB disease based on a lesion
size ≤3 cm and the presence of pleural invasion (PL). Univariate and multivariate analyses of recurrence-free survival
(RFS) were performed with age, sex, PL, and vascular invasion (blood vessel invasion [v] and lymphatic vessel
invasion [ly]) as variables. To examine vascular invasion, hematoxylin-eosin (HE), Elastica van Gieson staining, and
immunostaining with anti-podoplanin antibody were performed. The presence or absence of v and ly was
recorded; the number of involved vessels was counted. Survival rates were obtained using the Kaplan–Meier
method and log-rank test. Multivariate analyses were performed using the Cox proportional hazards model.
Results: RFS differed significantly between patients with no or one involved blood vessel (0 v or 1 v) and those
with ≥2 involved vessels (≥2 v). Similarly, RFS differed significantly between patients with no lymphatic vessel
involvement (0 ly) and those with one involved lymphatic vessel (1 ly). Thus, BVI(+) and BVI(−) were defined as
≥2 v and 0 v + 1 v, and LVI(+) and LVI(−) as ≥1 ly and 0 ly, respectively. BVI and LVI together represented tumor vessel
invasion (TVI). On multivariate analyses, PL and TVI were independently associated with recurrence. Additionally,
patients with p-Stage IA TVI(+) disease had a comparable recurrence rate to those with p-Stage IB disease.
Conclusions: Similar to PL, TVI is an important factor increasing the likelihood of recurrence. As HE staining alone is
insufficient for evaluating vascular invasion, specific staining is necessary. Moreover, patients with p-Stage IA TVI(+)
disease had a recurrence rate comparable to those with p-Stage IB disease; therefore, further studies should aim to
elucidate whether patients with p-Stage IA TVI(+) disease should be administered postoperative chemotherapy similar
to that received by p-Stage IB patients.
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Postoperative chemotherapy is currently administered to
patients with pathological stage (p-Stage) IB cancer, as
the efficacy of postoperative adjuvant chemotherapy in
these patients has been proven in several global studies
[1-3], and postoperative oral tegafur-uracil has proved
efficacious in a group of Japanese patients [4,5]. At
present, patients with p-Stage IA cancer often only receive
follow-up care after surgery because their outcome is
generally favorable without postoperative chemotherapy.
Therefore, it is difficult to determine the efficacy of
postoperative chemotherapy in these patients. In addition,
chemotherapy including tegafur-uracil is not currently
administered to patients with p-Stage IA disease, because
of the observed adverse effects. However, identification of
patients with p-Stage IA disease who have a high risk of
recurrence may result in further improvement in the
outcome of these patients.
Pleural invasion (PL) is a factor used in the tumor-node-
metastasis (TNM) classification, and its importance as a
poor prognostic factor has been demonstrated in several
studies [6-11]. In the 7th edition of the Union for Inter-
national Cancer Control TNM Classification, published in
2009, PL was reappraised as a pathological factor that
distinguishes p-Stage IA from p-Stage IB disease. While
invasion at the pleural surface denoted p-Stage IB in
the previous editions, invasion beyond the pleural elastic
layer became a criterion for determining p-Stage IB in the
7th edition. Travis et al. [12,13] recommended the use of
elastic fiber staining to improve the accuracy of its
determination.
Despite many previously published studies reporting
that vascular invasion, comprising blood vessel invasion
(v) and lymphatic vessel invasion (ly), was a strong inde-
pendent prognostic factor for recurrence in patients with
p-Stage I primary non-small cell lung cancer (NSCLC)
lesions ≤3 cm in diameter [10,14-23], it was not considered
a factor in the new TNM classification. This may explain
why there is no standard pathological assessment method
for vascular invasion.
Accordingly, we assessed vascular invasion in patients
with p-Stage I NSCLC lesions ≤3 cm diameter, using
hematoxylin-eosin (HE), Elastica van Gieson (EvG), and
D2-40 antibody immunohistological staining to examine
whether vascular invasion can be assessed using HE
staining alone. In addition, we evaluated whether vascu-
lar invasion was a useful prognostic factor in patients
with p-Stage I NSCLC lesions ≤3 cm in diameter. We
assessed the impact of vascular invasion by using the
number of invaded vascular channels as a prognostic
factor and compared its prognostic accuracy with the
presence or absence of PL. Furthermore, we investigated
whether v and ly are independent prognostic factors for re-
currence in patients with p-Stage I NSCLC by comparingthem with other factors, and examined whether differences
in recurrence rates according to vascular invasion are




A total of 467 patients with p-Stage I NSCLC who
underwent a radical lobectomy during the period between
January 2000 and December 2005 at Kanagawa Cancer
Center Hospital were evaluated. Totally, 335 patients were
diagnosed with p-Stage IA or IB disease based on a lesion
size ≤3 cm in diameter and the presence or absence of PL
(observation period: 8–4010 days; median: 2292 days); 132
patients were diagnosed with p-Stage IB disease with a
tumor diameter of 3–5 cm, irrespective of PL (observation
period: 34–3939 days; median: 1932.5 days). All patients
were consecutively enrolled, and none were excluded. The
patients did not receive preoperative treatment or
additional postoperative treatment during the recurrence-
free follow-up period. The study was performed according
to the requirements of the Institutional Review Board of
Kanagawa Cancer Center.
Study design
1) A study on the significance of vascular invasion in
patients with p-Stage I NSCLC lesions ≤3 cm in
diameter was performed in 335 patients with p-Stage
IA or IB cancer based on the presence of PL.
i) Objective determination of vascular invasion
A comparative study was performed focusing on
v, ly, and PL, which should be regarded as factors
causing the reclassification of T1 lung cancer
lesions ≤3 cm in diameter as T2a cancer in the
7th TNM classification. Univariate and
multivariate analyses were performed for
recurrence-free survival (RFS) periods with age,
sex, PL, and vascular invasion as variables.
To examine vascular invasion, samples for HE
and EvG staining and immunostaining with anti-
podoplanin antibody (clone D2-40) were newly
prepared from whole paraffin blocks of the largest
tumor sections. The stained samples were evalu-
ated in the aforementioned order to permit com-
parison of the findings of the respective stained
samples. First, the presence or absence of v and ly
in the largest sections was determined on HE stain-
ing alone. The criterion for the presence or absence
of invasion was destruction of the vascular wall or
further invasion into the vascular lumen. Later, the
presence or absence of v or ly was determined by
using EvG or D2-40 staining, respectively. The HE
staining assessment results remained unchanged






Number of patients 467 335 132
Age range Years 29–88 29–86 46–88
(mean/median) (65.4/66) (64/65) (68.6/69.5)
Sex Male 234 164 70
Female 233 171 62
Smoking status Smoker 247 170 77
Non-smoker 220 165 55
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40-stained samples. The entire surface of each sam-
ple was observed at × 10 magnification or up to × 40
in cases of unclear findings. Each sample was inde-
pendently examined microscopically by two
researchers (R.H. and T.Y.), and controversial cases
were evaluated using a multi-headed microscope
until they reached a consensus. The presence of PL
was determined by the detection of tumor cells on
the pleural surface on HE staining, or the observa-
tion of invasion beyond the pleural elastic layer on
EvG staining.p-Stage IA 299 299 0IB 168 36 132
Histological
differentiation
Adenocarcinoma 387 288 99
Squamous cell 47 24 23
carcinoma
Others 33 23 10
Recurrence 51 28 23
Deaths Present 81 45 36
Absent 386 290 96
(Cause of death) (Lung cancer) (37) (18) (19)ii) Assessment of the number of invaded vessels
The numbers of invaded blood and lymphatic
vessels were counted in patients with lung cancer
lesions ≤3 cm in diameter that were positive for
vascular invasion on EvG or D2-40 staining. The
entire surface of each sample was observed at ×
10 magnification or up to × 40 in cases of
unclear findings. Each case was independently
examined microscopically by two researchers,
and controversial cases were discussed until they
reached an agreement.
2) A study on the relationship between vascular
invasion, and p-Stages IA and IB included patients
with p-Stage IB disease and a pathological tumor
diameter of >3 cm. They were evaluated for the
presence or absence of v or ly and the number of
invaded vessels on EvG staining or D2-40, respectively.
The protocol used was similar to that mentioned
previously. p-Stage I was subdivided into p-Stage IA
and IB according to the presence or absence of
vascular invasion and the number of invaded
vessels, and the results were compared between
the two groups.
Observation period and statistical analysis
All analyses were performed for the observation period
(from the date of surgery to recurrence or the last known
recurrence-free date). The recurrence date was defined as
the date when recurrence was observed by using imaging
studies. Statistical analyses were performed using the Stat-
istical Package for the Social Sciences (Dr SPSS II for
Windows, Tokyo, Japan, released 2001) software. Survival
rates were calculated using the Kaplan-Meier method and
analyzed using the log-rank test. Multivariate analyses
were performed using the Cox proportional hazards model.
Differences were considered significant when p < 0.05.
Results
Patient characteristics
Table 1 shows the patients’ characteristics. The age range
for the 335 patients with p-Stage IA or IB disease basedon PL was 29–86 years (mean, 64 years; median, 65 years).
There were 164 male and 171 female patients. A total of
170 patients were smokers, and 165 were non-smokers.
Two hundred and ninety-nine patients were diagnosed
with p-Stage IA disease and 36 with p-Stage IB disease
owing to the presence of PL. Two hundred and eighty-
eight patients had adenocarcinoma, 24 had squamous cell
carcinoma, and 23 had other cancers (e.g., large cell
neuroendocrine carcinoma and large cell carcinoma).
Recurrence was observed in 28 patients.
The age range of the 132 patients with p-Stage IB
NSCLC lesions 3–5 cm in diameter was 46–88 years
(mean, 68.6 years; median, 69.5 years). There were 70 male
and 62 female patients. Seventy-seven patients were
smokers, and 55 were non-smokers. Ninety-nine patients
had adenocarcinoma, 23 had squamous cell carcinoma,
and 10 had other cancers (e.g., large cell neuroendocrine
carcinoma and large cell carcinoma). Recurrence was
observed in 23 patients.
Significance of vascular invasion in patients with p-Stage
I NSCLC lesions ≤3 cm in diameter
i) Objective determination of vascular invasion
Figure 1A contains representative images of vascular
invasion on HE and other staining methods, and
Figure 1B shows representative cases of false-negative
vascular invasion identified on HE staining. Of the 30
patients diagnosed with v on HE staining alone, 2 were
Figure 1 (See legend on next page.)
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Figure 1 Detection of vascular invasion by hematoxylin-eosin (HE) staining and other staining methods. A: Representative case of
vascular invasion by HE staining and confirmed using other staining methods. a) HE staining for the diagnosis of blood vessel invasion (v).
b) Elastica van Gieson staining to confirm v in the same patient. c) HE staining identified multiple instances of lymphatic vessel invasion (ly).
d) D2-40 staining to confirm ly in the same patient. B: Representative case of false-negative vascular invasion identified on HE staining.
a) v could not be determined on HE staining. b) Elastica van Gieson staining showed v in the same patient. c) Lymphatic vessel invasion (ly)
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patients diagnosed as not having v on HE staining, v
was detected in 33 on EvG staining (false negatives;
Table 2). Similarly, of 15 patients showing ly on HE
staining alone, 3 were found not to have ly on D2-40
staining. Conversely, of the 320 patients diagnosed as
not having ly on HE staining, ly was detected in 39 on
D2-40 staining (Table 3).Table 4 shows the sensitivity and specificity of HE
staining of v and ly versus EvG and D2-40 staining,
which are recognized as gold standards for v and ly,
respectively. Detection frequencies of both v and ly
on HE staining showed high specificity, but very low
sensitivity. Therefore, we decided to base v on the re-
sults of EvG staining and ly on the results of D2-40
staining.
ii) Assessment according to the number of invaded vessels
The 335 patients with tumors ≤3 cm in diameter were
classified according to the number of invaded vessels.
RFS was determined by dividing patients according to
the presence and absence of v and ly following EvG
and D2-40 staining, respectively. The probability of
recurrence differed significantly between patients
with a single involved vessel (1 v) compared to
those with two or more involved vessels (≥2 v;
p = 0.0131), whereas the risk of recurrence did not
differ significantly between patients with no vessel
involvement (0 v) and those in the 1 v group (p =
0.3673; Figures 2A, B). Similarly, the probability of
recurrence differed significantly between patients
with no lymphatic vessel invasion (0 ly) compared
to those with invasion of one lymphatic vessel
(1 ly; p = 0.0009), whereas the risk of recurrence
was not significantly different between patients
with 1 ly and those with invasion of two or more
lymphatic vessels (≥2 ly; Figures 3A, B).e 2 Hematoxylin-eosin (HE) and Elastica van Gieson




v(−) 33 272From this point, v was classified as 0 + 1 v or ≥2 v, de-
noting BVI(−) and BVI(+) invasion, respectively; ly
was classified as 0 ly or ≥1 ly, denoting LVI(−) and
LVI(+) invasion, respectively. Furthermore, BVI and
LVI together represented tumor vessel invasion (TVI).
iii)Analysis of RFS in NSCLC patients with lesions
≤3 cm in diameterTabl
invas
antib
HEPL was observed in 36 of 335 patients with NSCLC
lesions ≤3 cm in diameter. Univariate analyses
revealed significant differences in the duration of
RFS according to the presence or absence of PL,
BVI, and LVI (PL, p < 0.0001; BVI, p < 0.0001; LVI,
p = 0.0001; Table 5). Multivariate analyses revealed
that all of the aforementioned factors were
independently involved in recurrence (PL, hazard
ratio [HR] = 2.799; BVI, HR = 5.669; LVI, HR = 2.335;
Table 6). In addition, multivariate analyses also
revealed that TVI was predictive of recurrence
(HR = 6.946; Table 7).The 5-year RFS rates were 94.5%, 74.6%, 96.2%,
62.2%, 94.6%, and 79.7% for the PL(−), PL(+), BVI(−),
BVI(+), LVI(−), and LVI(+) groups, respectively
(Table 5). Recurrence rates were compared between
patients with and without PL. Of 299 PL(−) patients
with NSCLC lesions ≤3 cm in diameter, 56 were
TVI(+), and 11 of these (19.6%) experienced recur-
rence; of 243 TVI(−) patients, 7 (2.9%) displayed re-
currence. Thus, a significant difference was observed
between the two groups (p <0.0001; Figure 4).
Relationships between vascular invasion, and p-Stages IA
and IB
Patients with p-Stage IA disease were divided into TVI(+)
(IA(+) group) and TVI(−) groups (IA(−) group), and
compared with 168 p-Stage IB patients who underwente 3 Comparison of frequency of lymphatic vessel






Table 4 Sensitivity and specificity of hematoxylin-eosin
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patients with p-Stage IB NSCLC lesions ≤3 cm in dia-
meter; IB group). When the IA(+) and IA(−) groups were
compared with the IB groups, there was no significant dif-
ference in survival for IA(+) (p = 0.8848), in contrast, sur-
vival was significantly different for the IA(−) group (p <
0.00001; Figure 5A).
Similarly, patients with p-Stage IB disease were divided
into TVI(+) (IB(+) group) and TVI(−) (IB(−) group)
groups, and compared. A significant difference in survival
was observed between the IB(+) and IB(−) groups
(p = 0.0004). In addition, whereas no significant difference
was observed between the IA(+) and IB(−) groups
(p = 0.1309), the IB(−) group displayed better survival than
the IA(+) group (Figure 5B). The 5-year RFS rates were
97.9%, 79.7%, 81.3%, 89.9% and 67.7% for the IA(−), IA(+),
total IB, IB(−), and IB(+) groups, respectively.
Discussion
In recent years, vascular invasion has been considered
an important prognostic factor for patients with p-Stage
I NSCLC without metastasis to the lymph nodes
[17-23]. Although it is generally believed that HE stain-
ing alone is insufficient for vascular invasion diagnoses,
few studies have compared HE staining with immuno-
staining or other specific staining for vascular invasion.Figure 2 Recurrence-free survival according to the number of invad
and ≥2 v (n = 37) cases. B) Comparison between 0 v + 1 v (n = 298) andSeveral vascular markers have been previously used.
CD31 and CD34 are reactive with vascular endothelial
cells; however, CD31 exhibits cross-reaction with platelets,
monocytes, and macrophages, and CD34 displays cross-
reaction with hematological stem cells and mesenchymal
cells. We decided to use EvG staining and podoplanin
immunostaining because the former illustrates the
blood vessels and clarifies vascular destruction by
tumor cells. Podoplanin depicts lymphatic endothelium
in the mesenchyme only. Given the difficulty in performing
EvG and D2-40 staining of the entire tumor section for all
patients in a diagnostic setting, we used the largest tumor
sections to ensure realistic representative values (1–5 slide
glasses per patient; mean, 1.5 slide glasses per patient in
the current study).
We demonstrated that HE staining alone is not suffi-
cient to diagnose vascular invasion accurately, by first
examining the diagnosis by HE staining alone, and then
adding EvG and D2-40 staining. As shown in Tables 2, 3
and 4, although diagnosis of BVI on HE staining alone
revealed significant differences in both univariate and
multivariate analyses (HR = 3.945; p < 0.0001 and p =
0.002, respectively), it was apparent that this diagnosis
had an inferior sensitivity, as the diagnosis was missed in
many patients and their risk of recurrence was not ac-
curately diagnosed. Therefore, HE staining alone cannot
accurately identify vascular invasion as similar results
were obtained for the diagnosis of ly. HE staining is
likely to yield false-negative results in patients who have
vascular channels that are difficult to recognize by HE
staining alone. This can be because of the destruction of
the existing vascular lumen structure, small gaps be-
tween the vascular wall and tumor cells, and extremely
dense tumors with solid components which results in aned blood vessels. A) Comparison of 0 v (n = 274), 1v (n = 24),
≥2 v (n = 37) cases.
Figure 3 Recurrence-free survival according to the number of invaded lymphatic vessels. A) Comparison of 0 ly (n = 284), 1 ly (n = 20),
and ≥2 ly (n = 31) cases. B) Comparison between 0 ly (n = 284) and ≥1 ly (n = 51) cases.
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for false-positive results following HE staining include a
tumor in a prominently thickened alveolar wall owing to
advanced fibrosis, easily misidentified as blood vessels,
and the presence of tumor cells in gaps created as arti-
facts during sample preparation. The diagnosis of vascu-
lar invasion on HE staining alone may be dependent on
the skills of the observer. Although diagnosis by more
than one observer may increase accuracy, the addition
of EvG and D2-40 staining enables both experienced
evaluators and other observers to diagnose vascularTable 5 Recurrence-free survival and clinicopathological
characteristics
Variables No. RFP (%) Univariate P value
All 335 92.3
Age (years) ≥65 178 94.4 0.3224
<65 157 90.1
Sex Male 164 91.2 0.3002
Female 171 93.5
Smoking status Smoker 165 94.5 0.1013
Non-smoker 170 90.4
PL (−) 299 94.5 <0.0001
(+) 36 74.6
BVI Negative (0 or 1) 298 96.2 <0.0001
Positive (≥2) 37 62.2
LVI Negative (0) 284 94.6 0.0001
Positive (≥1) 51 79.7
TVI (−) 262 97.3 <0.0001
(+) 73 74.6
PL, pleural invasion; BVI, blood vessel invasion; LVI, lymphatic vessel invasion;
TVI, tumor vessel invasion.invasion readily, and is extremely important for a more
accurate diagnosis and assessment of recurrence factors.
Currently, vascular invasion is often assessed using
vague qualitative expressions such as “present”, “slight”,
and “moderate”. Therefore, we assessed whether there
was a significant difference in evaluation of vascular in-
vasion by counting the number of invaded blood vessels
on the entire surface of the largest tumor section. A
significant difference was noted in the initial compari-
son between v(+) and v(−), probably because of the pre-
dominance of patients with ≥2 v. The most important
aspect of the diagnosis of v is not whether it is present
or absent, but instead, it is the presence of ≥2 v in the
largest tumor section, i.e., the “degree” of v at a given
level (assessment considering the BVI). In the diagnosis
of ly, a significant difference was observed between the
0 ly and 1 ly groups (p <0.0001), with no further significant
difference observed between the 1 ly and ≥2 ly groups.
These findings indicate the importance of “presence” in ly
diagnosis (assessment considering the LVI).Table 6 Multivariate analyses of risk factors for
recurrence including blood vessel invasion and lymphatic
vessel invasion
Variable p HR 95% CI
Age 0.185 1.676 0.780–3.600
Sex 0.853 0.930 0.429–2.015
PL 0.016 2.799 1.212–6.464
BVI 0.000 5.669 2.454–13.095
LVI 0.040 2.335 1.039–5.248
PL, pleural invasion; BVI, blood vessel invasion; LVI, lymphatic vessel invasion;
HR, hazard ratio; CI, confidence interval.
Table 7 Multivariate analyses of risk factors for
recurrence including tumor vessel invasion
p HR 95% CI
Age 0.114 1.851 0.863–3.969
Sex 0.886 0.945 0.438–2.039
PL 0.008 3.015 1.333–6.821
TVI 0.000 6.946 2.980–16.189
PL, pleural invasion; TVI, tumor vessel invasion; HR, hazard ratio; CI,
confidence interval.
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cular invasion was a significant prognostic factor
[10,15-17,19-23]; however, these studies only included
patients with a high degree of vascular invasion. Re-
cently, Kaseda et al. reported that the presence, but not
the extent of invasion, was a significant prognostic fac-
tor; however, they used glass slides that were previously
stained using two different elastic fiber staining methods,
which might have resulted in discoloration and have
affected the certainty of the evaluation [24]. The assess-
ment should be performed under controlled conditions
wherever possible, as applied in this study. Some authors
studied other aspects of vascular invasion. Brechot et al.
found no prognostic significance when they compared
invasion of arteries and veins [14]. Saijo et al. reported
the prognostic significance of the location of lymphatic
vessels (inside vs. outside the tumor nodule) [18]. The
location of vascular invasion might be an important
prognostic factor, and further evaluation is warranted.
Image analysis of NSCLC microvasculature is one of
the methods used for vessel evaluation. Kayser et al.
measured tumor vascularization with an anti-CD34Figure 4 Recurrence-free survival for patients without pleural invasio
TVI(+) (n = 56) and TVI(−) (n = 243) cases.antibody and quantitative image analysis [25,26]. Szöke
et al. reported that an increase in microvessel volume
fraction pointed to a poorer survival rate [27].
Generalization of image analysis on specimens would
ensure reproducible and accurate vessel evaluation in
daily practice.
The current TNM classification states that T1 should be
upstaged to T2 when PL is identified. However, the pres-
ence of vascular invasion is still not a factor considered in
the p-Stage classification despite it being believed to be
significantly associated with recurrence [17-23]. Accord-
ingly, we assessed vascular invasion by multivariate ana-
lyses and found that PL, BVI, and LVI were independent
factors for recurrence. In addition, the prognostic value of
BVI (HR = 5.669) was superior to that of PL (HR = 2.799),
indicating that BVI is more strongly associated with re-
currence than PL. As there is no criterion for changing
the p-Stage classification according to vascular inva-
sion, patients with NSCLC lesions ≤3 cm in diameter
without PL are all diagnosed with p-Stage IA disease.
However, given that the classification of such patients
according to BVI results in significantly different recur-
rence rates, the present classification of these patients
in the same p-Stage could be improved.
Consequently, we compared p-Stage IA patients with
168 p-Stage IB patients who underwent resection using
the same operative procedure at approximately the same
time. Figure 5A shows that the survival of the IA(−)
group was significantly different from that of both the
IA(+) and IB groups, whereas no difference in survival
was noted between the IA(+) and IB groups. However,
the IB(−) group tended to have better survival than then according to tumor vessel invasion (TVI). Comparison between
Figure 5 Recurrence-free survival according to p-Stage and presence of tumor vessel invasion (TVI). A) Comparison of IA(−) (n = 243),
IA(+) (n = 56), and IB (n = 168). B) Comparison of IA(−) (n = 243), IA(+) (n = 56), IB(−) (n = 103), and IB(+) (n = 65). Five-year recurrence-free survival
rate (%): IA(−), 97.9%; IA(+), 79.7%; IB, 81.3%; IB(−), 81.3%; and IB(+), 67.7%.
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therapy is currently recommended for p-Stage IB pa-
tients [1-6], p-Stage IA patients with TVI are only
monitored and do not receive treatment postoperatively.
The administration of postoperative treatment equiva-
lent to that given to p-Stage IB patients could lead to an
improved outcome for p-Stage IA patients u.Conclusions
TVI is an important factor that may increase the recur-
rence rate; a similar effect by PL was considered significant
when the TNM classification system was revised. Although
HE staining alone is not sufficient to diagnose vascular
invasion, the addition of specific staining and immuno-
staining may increase objectivity. In the diagnosis of v
in particular, the extent of invasion (“degree” of BVI) is
more strongly associated with recurrence than PL. In
the future, this variable should be considered to determine
whether p-Stage IA TVI(+) patients should be adminis-
tered postoperative chemotherapy similar to that received
by patients with p-Stage IB disease, given that they have a
comparable risk of recurrence. A further prospective study
with a larger cohort is needed to clarify the efficacy of
postoperative treatment for p-Stage IA patients with TVI.
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